Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

stu4 Jul. 11 at 4:03 PM

$AGIO Yah , lol a Sunday …open the bureau up, for these clowns , hahaha

0 · Reply

stu4 Jul. 11 at 4:02 PM

$AGIO a fcuking Sunday ..it figures for these misfits to use Nov 1 …like their Sept date last year that was a sunday and , they MISSED the date ….these loser execs , will say “ FDA extended the approval on October 29th to another date , yet an FDA official announcement should come that day , a FCUKING THURSDAY , hahahaha. @OctahedronOmega EDDIE , hahaha

0 · Reply

OctahedronOmega Jul. 8 at 2:50 PM

$AGIO New PDUFA date set for 2026-11-01. Clean catalyst on the calendar now for Agios. Still a binary setup into the review date, with the timeline giving traders a clearer window to watch.

0 · Reply

fda_tracker Jul. 8 at 2:19 PM

$AGIO New PDUFA Date 2026-11-01 Agios Pharmaceuticals, Inc. Link: https://www.globenewswire.com/news-release/2026/07/07/3323022/31990/en/u-s-fda-grants-priority-review-to-agios-snda-for-mitapivat-in-sickle-cell-disease.html Calendar: http://www.fdatracker.com/fda-calendar/

0 · Reply

Spicy_Trade Jul. 8 at 2:46 AM

Agios Pharmaceuticals, Inc. ( $AGIO ) SpicyTrade - Daily Stock Analysis https://youtu.be/AhhVj93WWC8?si=hSxO4nQsU3C6keIa

0 · Reply

Avocado_smash Jul. 8 at 1:20 AM

$AGIO Breaking out 🚀

0 · Reply

Merlintrader Jul. 7 at 7:38 PM

$AGIO

0 · Reply

stu4 Jul. 7 at 6:13 PM

$AGIO I’ll add ..Leerink Partners were 100% wrong on ALNY in 2017 …the stock went from $28 to $155 , and then further in the subsequent years !!!! Whomever is their biotech analysts, they suck at it !!! ( I a holder of ALNY since 2017 from $28 !! )

0 · Reply

LewisDaKat Jul. 7 at 6:00 PM

$AGIO Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related) https://marketwirenews.com/stock/agio/news/here-s-why-agios-pharmaceuticals-stock-soared-today--7297408093707042.html?utm_source=stocktwits

0 · Reply

MajorBigBull Jul. 7 at 5:04 PM

$AGIO

0 · Reply

Agios Pharmaceuticals rises 13.5%

2026-07-07T15:40:11.000Z - 7 days ago

Leerink sees Priority Review designation as positive sign for Agios’ mitapivat

2026-07-07T15:25:11.000Z - 7 days ago

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

2026-07-07T14:06:03.000Z - 7 days ago

Agios Pharmaceuticals rises 12.9%

2026-07-07T13:20:27.000Z - 7 days ago

Agios Pharmaceuticals price target raised to $46 from $40 at BofA

2026-07-07T13:15:43.000Z - 7 days ago

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

2026-07-07T11:31:01.000Z - 7 days ago

Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital

2026-07-07T11:16:10.000Z - 7 days ago

Agios Pharmaceuticals granted priority review for mitapivat sNDA

Jul 7, 2026, 7:00 AM EDT - 8 days ago

U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

Jun 29, 2026, 7:00 AM EDT - 16 days ago

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

2026-06-15T10:06:50.000Z - 4 weeks ago

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

2026-06-14T20:35:05.000Z - 4 weeks ago

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

Jun 13, 2026, 9:00 AM EDT - 4 weeks ago

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Jun 13, 2026, 9:00 AM EDT - 4 weeks ago

Agios Pharmaceuticals Transcript: EHA 2026

Jun 13, 2026, 9:00 AM EDT - 4 weeks ago

Agios Pharmaceuticals Slides: FY 2026

2026-06-10T23:45:10.000Z - 4 weeks ago

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Agios Pharmaceuticals Transcript: Status update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Agios Pharmaceuticals Slides: Status update

Jun 1, 2026, 8:00 AM EDT - 6 weeks ago

Agios Pharmaceuticals Press release: Status update

2026-06-01T09:13:35.000Z - 6 weeks ago

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

Jun 1, 2026, 5:00 AM EDT - 6 weeks ago

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

2026-05-29T15:28:43.000Z - 6 weeks ago

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

May 29, 2026, 7:21 AM EDT - 6 weeks ago

Agios scraps blood cancer drug program after study miss

2026-05-29T11:08:17.000Z - 6 weeks ago

Agios will not advance tebapivat in lower-risk myelodysplastic syndromes

May 29, 2026, 7:00 AM EDT - 6 weeks ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

2026-05-22T14:25:48.000Z - 7 weeks ago

Agios announces EC grants marketing authorization for PYRUKYND

May 22, 2026, 10:18 AM EDT - 7 weeks ago

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

May 22, 2026, 9:15 AM EDT - 7 weeks ago

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 19, 2026, 11:00 AM EDT - 2 months ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-12T19:25:15.000Z - 2 months ago

Agios Pharma submits sNDA to FDA for U.S. accelerated approval of mitapivat

2026-05-12T19:15:22.000Z - 2 months ago

Agios Pharmaceuticals to present mitapivat data at EHA Congress

May 12, 2026, 9:31 AM EDT - 2 months ago

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026, 9:30 AM EDT - 2 months ago

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

2026-04-30T12:15:00.000Z - 2 months ago

Agios Pharmaceuticals price target lowered to $36 from $39 at Truist

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Quarterly report: Q1 2026

2026-04-29T11:02:17.000Z - 2 months ago

Agios Pharmaceuticals reports Q1 EPS ($1.69), consensus ($1.79)

Apr 29, 2026, 6:30 AM EDT - 2 months ago

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

2026-04-21T12:54:10.000Z - 3 months ago

Agios Pharmaceuticals price target lowered to $41 from $44 at BofA

NVO

Apr 6, 2026, 7:00 AM EDT - 3 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Mar 31, 2026, 8:45 AM EDT - 3 months ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 2, 2026, 11:50 AM EST - 4 months ago